查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1601096

多癌筛检市场：按产品类型、测试类型、技术、癌症类型、最终用户 - 2025-2030 年全球预测

Multicancer Screening Market by Product (AI and Machine Learning-Based Platforms, Blood-Based Tests, Breath Analysis Tests), Test Type (In-vitro diagnostics, Laboratory Developed Tests), Technology, Cancer Type, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年多筛检市场价值为14亿美元，预计2024年将达到15.3亿美元，复合年增长率为9.90%，预计到2030年将达到27.2亿美元。

多癌筛检代表了早期癌症检测的革命性转变，旨在在症状出现之前透过一次测试识别多种癌症类型。由于癌症发病率和死亡率不断上升，这种方法变得越来越必要，这凸显出早期检测对于提高存活率至关重要。多种癌症筛检预计将主要应用于临床环境和常规健康检查，以促进早期发现高风险族群，例如有癌症家族病史或遗传倾向的人。最终用途范围主要包括医院、诊断实验室和癌症研究中心。推动市场成长的是基因组学和生物资讯学的技术进步，这些技术进步使得癌症生物标记的检测更加准确和全面。人工智慧在资料分析中的整合也有助于扩展多种癌症筛检能力。此外，公众意识的提高和个人化医疗的采用正在创造潜在的机会。然而，高成本、监管障碍以及测试敏感性和特异性问题等挑战可能会阻碍市场成长。有关遗传资讯的伦理考量和资料隐私问题变得更加复杂。为了克服这些限制，需要进行研究，重点是透过技术创新降低成本并提高检测精度。新型生物标誌物的整合以及使用人工智慧进行高级风险评估可以极大地推动创新。研究更好的资料管理工具和安全平台来处理敏感的遗传资讯也至关重要。透过与专门从事人工智慧和巨量资料分析的高科技公司合作，还有机会改善检测演算法并改善患者治疗结果。总体而言，只要克服这些挑战并优化最尖端科技的应用以满足不断变化的医疗保健需求，多癌症筛检市场有望显着成长。

主要市场统计
基准年[2023] 14亿美元
预测年份 [2024] 15.3亿美元
预测年份 [2030] 27.2亿美元
复合年增长率（%） 9.90%

市场动态：揭示快速发展的多种癌症筛检市场的关键市场洞察

供需的动态交互作用正在改变多种筛检市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 癌症盛行率增加和老化速度加快
    • 多项政府措施促进医疗机构中的多种癌症筛检
  • 市场限制因素
    • 与多种筛检相关的耗时程序和高成本
  • 市场机会
    • 液态切片的潜在利用和多癌症检测 (MCD) 研究中心的增加
    • 活性化癌症诊断和治疗方法开发的研究开发活动
  • 市场挑战
    • 安全性和有效性资料不足，对测试性能变化的担忧

波特五力：驾驭多种癌症筛检市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解多种筛检市场的外部影响

外部宏观环境因素在塑造多癌症筛检市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解多癌症筛检市场的竞争状况

对多种筛检市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵多癌症筛检市场供应商的绩效评估

FPNV定位矩阵是评估多癌症筛检市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：全面分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 癌症发生率增加和人口老化
      • 政府努力促进医疗机构中的多种癌症筛检
    • 抑制因素
      • 多种癌症筛检过程耗时且高成本
    • 机会
      • 液态生物检体的潜在用途和多种癌症检测 (MCD) 研究中心的兴起
      • 增加癌症诊断治疗程序的研发活动
    • 任务
      • 对安全性和有效性资料不足以及测试性能变化的担忧
  • 市场区隔分析
    • 产品：透过人工智慧驱动的筛检和诊断技术的突破性创新改善早期癌症检测
    • 测试类型：体外诊断和实验室开发的测试是早期癌症检测和改善患者预后的首选。
    • 技术：PCR 因其早期检测效率和准确性而受到青睐
    • 癌症类型：透过多学科筛检的进步关注创新和可及性
    • 最终用户：协调创新和护理，解决学术、诊断和医疗保健领域的多个癌症筛检优先事项
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章多种癌症筛检市场：副产品

  • 基于人工智慧和机器学习的平台
  • 验血
  • 呼气分析测试
  • 粪便检查
  • 基因组/测试组
  • 影像检查
    • 电脑断层扫描
    • 磁振造影
    • 正子断层扫描
  • 唾液和口腔拭子测试
  • 组织检查
  • 尿液检查

第七章按测试类型分類的多种癌症筛检市场

  • 体外诊断
  • 实验室开发测试

第八章多种癌症筛检市场：依技术分类

  • 萤光原位杂合技术
  • 免疫组织化学
  • 次世代定序
  • 聚合酵素链锁反应

第九章按癌症类型分類的多种癌症筛检市场

  • 大脑/神经系统
  • 乳房/妇科
  • 内分泌
  • 胃肠道
  • 泌尿生殖系统
  • 造血系统恶性
  • 肺
  • 肉瘤
  • 皮肤

第 10 章 多种癌症筛检市场：依最终用户分类

  • 学术/研究机构
  • 诊断和临床实验室
  • 医院

第十一章美洲多种癌症筛检市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区多种癌症筛检市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲多癌症筛检市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 策略性资金筹措将加速 Freenome 早期癌症检测技术的进步
    • PanGIA Biotech 利用液态生物检体平台改进致癌性疾病的检测
    • Exact Sciences Corp. 的遗传性癌症筛检测试「Riskguard」简介
    • SeekIn Inc. 和 Oncolnv 策略联盟加强全球癌症检测工作
    • AnchorDx 和 DiaCarta 之间的合作将彻底改变全球癌症检测
    • 燃石生物科技的 OverC 多枪检测血液检测获得全球认可
    • Elypta 获得 ISO 13485:2016 认证，推动基于 GAGome 的多种癌症检测
    • Freenome 的策略性收购透过 Oncimmune Ltd 的先进诊断技术增强了癌症检测能力
    • Lucens 透过创新的 MCED 血液检测改善癌症检测：在美国的策略公告

公司名单

  • ANPAC Bio-Medical Science Co., Ltd.
  • Burning Rock Biotech Limited
  • Caris Life Sciences
  • Coyne Medical Ltd.
  • Delfi Diagnostics, Inc.
  • Elypta AB
  • EpiCypher, Inc.
  • Epigenomics AG
  • Exact Sciences Corporation
  • Foundation Medicine, Inc.
  • Freenome Holdings, Inc.
  • Fulgent Genetics, Inc.
  • Gene Solutions
  • Grail, LLC by Illumina, Inc.
  • Guangzhou AnchorDx Medical Co., Ltd.
  • Guardant Health, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Lucence Health Inc.
  • Micronoma, Inc.
  • MiRXES Pte Ltd.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Naveris, Inc.
  • NeoGenomics Laboratories
  • OneTest
  • Siemens Healthineers AG
  • StageZero Life Sciences. Ltd.
Product Code: MRR-5C6F41F5AFE7

The Multicancer Screening Market was valued at USD 1.40 billion in 2023, expected to reach USD 1.53 billion in 2024, and is projected to grow at a CAGR of 9.90%, to USD 2.72 billion by 2030.

Multicancer screening represents an innovative shift in early cancer detection, aiming to identify multiple cancer types through a single test before symptoms appear. This approach has become increasingly necessary due to rising cancer incidence and mortality rates, underscoring the critical need for early detection to improve survival rates. Multicancer screening is projected to be applied primarily in clinical settings and routine health check-ups, enhancing early detection among high-risk populations, such as those with a family history of cancer or existing genetic predispositions. The end-use scope primarily includes hospitals, diagnostic laboratories, and cancer research centers. Market growth is fueled by technological advancements in genomics and bioinformatics, allowing for more accurate and comprehensive detection of cancer biomarkers. The integration of AI in data analysis also contributes to the expansion of multicancer screening capabilities. Additionally, increasing public awareness and the adoption of personalized medicine are generating potential opportunities. However, challenges such as high costs, regulatory hurdles, and issues related to the sensitivity and specificity of tests can impede market growth. Ethical considerations and data privacy concerns regarding genetic information further add complexity. To overcome these limitations, research should focus on reducing costs through technological innovation and enhancing test accuracy. The integration of novel biomarkers and leveraging AI for advanced risk assessment could significantly propel innovation. Researching better data management tools and secure platforms for handling sensitive genetic information is also vital. Opportunities lie in partnerships with tech firms specializing in AI and big data analytics to refine detection algorithms and improve patient outcomes. Overall, the multicancer screening market is poised for substantial growth, contingent upon overcoming these challenges and optimizing the application of cutting-edge technologies to meet evolving healthcare demands.

KEY MARKET STATISTICS
Base Year [2023] USD 1.40 billion
Estimated Year [2024] USD 1.53 billion
Forecast Year [2030] USD 2.72 billion
CAGR (%) 9.90%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Multicancer Screening Market

The Multicancer Screening Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cancer disease and rising aging population
    • Several government initiatives promoting multicancer screening in healthcare facilities
  • Market Restraints
    • Time-consuming procedures coupled with high cost associated with multicancer screening
  • Market Opportunities
    • Potential utilization of liquid biopsy and rising multicancer detection (MCD) research centers
    • Rising R&D activities for the development of cancer diagnostics treatment procedures
  • Market Challenges
    • Concerns associated with adequate safety and efficacy data and variability in test performance

Porter's Five Forces: A Strategic Tool for Navigating the Multicancer Screening Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Multicancer Screening Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Multicancer Screening Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Multicancer Screening Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Multicancer Screening Market

A detailed market share analysis in the Multicancer Screening Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Multicancer Screening Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Multicancer Screening Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Multicancer Screening Market, highlighting leading vendors and their innovative profiles. These include ANPAC Bio-Medical Science Co., Ltd., Burning Rock Biotech Limited, Caris Life Sciences, Coyne Medical Ltd., Delfi Diagnostics, Inc., Elypta AB, EpiCypher, Inc., Epigenomics AG, Exact Sciences Corporation, Foundation Medicine, Inc., Freenome Holdings, Inc., Fulgent Genetics, Inc., Gene Solutions, Grail, LLC by Illumina, Inc., Guangzhou AnchorDx Medical Co., Ltd., Guardant Health, Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Lucence Health Inc., Micronoma, Inc., MiRXES Pte Ltd., Myriad Genetics, Inc., Natera, Inc., Naveris, Inc., NeoGenomics Laboratories, OneTest, Siemens Healthineers AG, and StageZero Life Sciences. Ltd..

Market Segmentation & Coverage

This research report categorizes the Multicancer Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across AI and Machine Learning-Based Platforms, Blood-Based Tests, Breath Analysis Tests, Fecal Tests, Gene Panels/Test Panels, Imaging Tests, Saliva & Buccal Swab Test, Tissue Test, and Urine-Based Tests. The Imaging Tests is further studied across Computed Tomography, Magnetic Resonance Imaging, and Positron Emission Tomography.
  • Based on Test Type, market is studied across In-vitro diagnostics and Laboratory Developed Tests.
  • Based on Technology, market is studied across Fluorescence In-Situ Hybridization, Immunohistochemistry, Next-Generation Sequencing, and Polymerase Chain Reaction.
  • Based on Cancer Type, market is studied across Brain/Nervous System, Breast & Gynecologic, Endocrine, Gastrointestinal, Genitourinary, Hematological Malignancies, Lung, Sarcoma, and Skin.
  • Based on End User, market is studied across Academic & Research Institutions, Diagnostic & Clinical Laboratories, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer disease and rising aging population
      • 5.1.1.2. Several government initiatives promoting multicancer screening in healthcare facilities
    • 5.1.2. Restraints
      • 5.1.2.1. Time-consuming procedures coupled with high cost associated with multicancer screening
    • 5.1.3. Opportunities
      • 5.1.3.1. Potential utilization of liquid biopsy and rising multicancer detection (MCD) research centers
      • 5.1.3.2. Rising R&D activities for the development of cancer diagnostics treatment procedures
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with adequate safety and efficacy data and variability in test performance
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Improvement in early cancer detection through revolutionary innovations in ai-enhanced screening and diagnostic technologies
    • 5.2.2. Test Type: In-vitro diagnostics and laboratorydeveloped tests are preferred for early cancer detection and improve patient outcomes
    • 5.2.3. Technology: Significant preference toward PCR for its efficiency in early detection and accuracy
    • 5.2.4. Cancer Type: Emphasizing innovation and accessibility through advancement in the multispeciality screening
    • 5.2.5. End-User: Harmonizing innovation and care to navigate multi cancer screening priorities across academic, diagnostic, and healthcare sectors
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Multicancer Screening Market, by Product

  • 6.1. Introduction
  • 6.2. AI and Machine Learning-Based Platforms
  • 6.3. Blood-Based Tests
  • 6.4. Breath Analysis Tests
  • 6.5. Fecal Tests
  • 6.6. Gene Panels/Test Panels
  • 6.7. Imaging Tests
    • 6.7.1. Computed Tomography
    • 6.7.2. Magnetic Resonance Imaging
    • 6.7.3. Positron Emission Tomography
  • 6.8. Saliva & Buccal Swab Test
  • 6.9. Tissue Test
  • 6.10. Urine-Based Tests

7. Multicancer Screening Market, by Test Type

  • 7.1. Introduction
  • 7.2. In-vitro diagnostics
  • 7.3. Laboratory Developed Tests

8. Multicancer Screening Market, by Technology

  • 8.1. Introduction
  • 8.2. Fluorescence In-Situ Hybridization
  • 8.3. Immunohistochemistry
  • 8.4. Next-Generation Sequencing
  • 8.5. Polymerase Chain Reaction

9. Multicancer Screening Market, by Cancer Type

  • 9.1. Introduction
  • 9.2. Brain/Nervous System
  • 9.3. Breast & Gynecologic
  • 9.4. Endocrine
  • 9.5. Gastrointestinal
  • 9.6. Genitourinary
  • 9.7. Hematological Malignancies
  • 9.8. Lung
  • 9.9. Sarcoma
  • 9.10. Skin

10. Multicancer Screening Market, by End User

  • 10.1. Introduction
  • 10.2. Academic & Research Institutions
  • 10.3. Diagnostic & Clinical Laboratories
  • 10.4. Hospitals

11. Americas Multicancer Screening Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Multicancer Screening Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Multicancer Screening Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Strategic Funding Fuels Freenome's Advancement in Early Cancer Detection Technology
    • 14.3.2. PanGIA Biotech Advances Multi-Cancer Detection with Liquid Biopsy Platform
    • 14.3.3. Introduction of Riskguard, A Hereditary Cancer Screening Test by Exact Sciences Corp
    • 14.3.4. Strategic Partnership Between SeekIn Inc. and Oncolnv to Enhance Global Cancer Detection Efforts
    • 14.3.5. Collaboration Between AnchorDx and DiaCarta to Revolutionize Global Cancer Screening
    • 14.3.6. Burning Rock Biotech Achieves Global Recognition with OverC Multi-Cancer Detection Blood Test
    • 14.3.7. Elypta Attains ISO 13485:2016 Certification, Advancing GAGome-Based Multicancer Detection
    • 14.3.8. Strategic Acquisition by Freenome Amplifies Cancer Screening Capabilities through Oncimmune Ltd's Advanced Diagnostics
    • 14.3.9. Lucence Advances Cancer Detection with Innovative MCED Blood Test: A Strategic Unveiling in the U.S.

Companies Mentioned

  • 1. ANPAC Bio-Medical Science Co., Ltd.
  • 2. Burning Rock Biotech Limited
  • 3. Caris Life Sciences
  • 4. Coyne Medical Ltd.
  • 5. Delfi Diagnostics, Inc.
  • 6. Elypta AB
  • 7. EpiCypher, Inc.
  • 8. Epigenomics AG
  • 9. Exact Sciences Corporation
  • 10. Foundation Medicine, Inc.
  • 11. Freenome Holdings, Inc.
  • 12. Fulgent Genetics, Inc.
  • 13. Gene Solutions
  • 14. Grail, LLC by Illumina, Inc.
  • 15. Guangzhou AnchorDx Medical Co., Ltd.
  • 16. Guardant Health, Inc.
  • 17. Invitae Corporation
  • 18. Laboratory Corporation of America Holdings
  • 19. Lucence Health Inc.
  • 20. Micronoma, Inc.
  • 21. MiRXES Pte Ltd.
  • 22. Myriad Genetics, Inc.
  • 23. Natera, Inc.
  • 24. Naveris, Inc.
  • 25. NeoGenomics Laboratories
  • 26. OneTest
  • 27. Siemens Healthineers AG
  • 28. StageZero Life Sciences. Ltd.

LIST OF FIGURES

  • FIGURE 1. MULTICANCER SCREENING MARKET RESEARCH PROCESS
  • FIGURE 2. MULTICANCER SCREENING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2030 (USD THOUSAND)
  • FIGURE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 6. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 14. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 16. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 18. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 20. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 24. MULTICANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. MULTICANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MULTICANCER SCREENING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2030 (USD THOUSAND)
  • TABLE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 6. MULTICANCER SCREENING MARKET DYNAMICS
  • TABLE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AI AND MACHINE LEARNING-BASED PLATFORMS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BLOOD-BASED TESTS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREATH ANALYSIS TESTS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY FECAL TESTS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANELS/TEST PANELS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 13. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 14. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 15. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 16. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 17. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 18. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SALIVA & BUCCAL SWAB TEST, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 19. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TISSUE TEST, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 20. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY URINE-BASED TESTS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 21. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 22. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY IN-VITRO DIAGNOSTICS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 23. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TESTS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 24. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 25. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY FLUORESCENCE IN-SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 26. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 27. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 28. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 29. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 30. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BRAIN/NERVOUS SYSTEM, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 31. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST & GYNECOLOGIC, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 32. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY ENDOCRINE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 33. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 34. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENITOURINARY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 35. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 36. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 37. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SARCOMA, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 38. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SKIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 39. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 40. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 41. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC & CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 42. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 43. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 44. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 45. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 46. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 47. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 48. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 49. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 50. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 51. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 52. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 53. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 54. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 55. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 56. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 57. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 58. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 59. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 60. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 61. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 62. CANADA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 63. CANADA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 64. CANADA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 65. CANADA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 66. CANADA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 67. CANADA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 68. MEXICO MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 69. MEXICO MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 70. MEXICO MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 71. MEXICO MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 72. MEXICO MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 73. MEXICO MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 74. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 75. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 76. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 77. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 78. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 79. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 80. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2018-2030 (USD THOUSAND)
  • TABLE 81. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 82. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 83. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 84. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 85. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 86. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 87. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 88. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 89. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 90. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 91. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 92. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 93. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 94. CHINA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 95. CHINA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 96. CHINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 97. CHINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 98. CHINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 99. CHINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 100. INDIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 101. INDIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 102. INDIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 103. INDIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 104. INDIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 105. INDIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 106. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 107. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 108. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 109. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 110. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 111. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 112. JAPAN MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 113. JAPAN MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 114. JAPAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 115. JAPAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 116. JAPAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 117. JAPAN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 118. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 119. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 120. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 121. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 122. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 123. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 124. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 125. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 126. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 127. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 128. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 129. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 130. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 131. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 132. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 133. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 134. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 135. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 136. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 137. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 138. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 139. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 140. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 141. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 142. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 143. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 144. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 145. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 146. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 147. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 148. THAILAND MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 149. THAILAND MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 150. THAILAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 151. THAILAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 152. THAILAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 153. THAILAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 154. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 155. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 156. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 157. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 158. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 159. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 167. DENMARK MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 168. DENMARK MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 169. DENMARK MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 170. DENMARK MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 171. DENMARK MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 172. DENMARK MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 173. EGYPT MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 174. EGYPT MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 175. EGYPT MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 176. EGYPT MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 177. EGYPT MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 178. EGYPT MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 179. FINLAND MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 180. FINLAND MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 181. FINLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 182. FINLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 183. FINLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 184. FINLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 185. FRANCE MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 186. FRANCE MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 187. FRANCE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 188. FRANCE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 189. FRANCE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 190. FRANCE MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 191. GERMANY MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 192. GERMANY MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 193. GERMANY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 194. GERMANY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 195. GERMANY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 196. GERMANY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 197. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 198. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 199. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 200. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 201. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 202. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 203. ITALY MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 204. ITALY MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 205. ITALY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 206. ITALY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 207. ITALY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 208. ITALY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 209. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 210. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 211. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 212. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 213. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 214. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 215. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 216. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 217. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 218. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 219. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 220. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 221. NORWAY MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 222. NORWAY MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 223. NORWAY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 224. NORWAY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 225. NORWAY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 226. NORWAY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 227. POLAND MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 228. POLAND MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 229. POLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 230. POLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 231. POLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 232. POLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 233. QATAR MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 234. QATAR MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 235. QATAR MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 236. QATAR MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 237. QATAR MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 238. QATAR MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 239. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 240. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 241. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 242. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 243. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 244. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 245. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 246. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 247. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 248. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 249. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 250. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 251. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 252. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 253. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 254. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 255. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 256. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 257. SPAIN MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 258. SPAIN MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 259. SPAIN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 260. SPAIN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 261. SPAIN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 262. SPAIN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 263. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 264. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 265. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 266. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 267. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 268. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 269. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 270. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 271. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 272. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 273. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 274. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 275. TURKEY MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 276. TURKEY MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 277. TURKEY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 278. TURKEY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 279. TURKEY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 280. TURKEY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 281. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 282. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 283. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 284. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 285. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 286. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 287. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 288. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 289. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 290. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 291. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 292. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 293. MULTICANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 294. MULTICANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2023